Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00215670
Status:
COMPLETED
Last Update Posted:
2006-05-03
First Post:
2005-09-14
Brief Title:
Study of the Safety Tolerability and Pharmacokinetics of 1 MgEye and 3 MgEye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration AMD
Sponsor:
Eyetech Pharmaceuticals
Organization:
Eyetech Pharmaceuticals
Study Overview
Official Title:
A Randomized Double-Masked Multi-Center Trial of the Safety Tolerability and Pharmacokinetics of 1 MgEye and 3 MgEye Intravitreal Injections of Pegaptanib Sodium Anti-Vegf Pegylated Aptamer Given Every 6 Weeks for 54 Weeks in Patients With Exudative Age-Related Macular Degeneration AMD
Status:
COMPLETED
Status Verified Date:
2006-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objectives of this study are to characterize the safety tolerability and pharmacokinetics of pegaptanib when given as 1 or 3mgeye intravitreous injections every 6 weeks for 54 weeks in patients with subfoveal choroidal neovascularization CNV secondary to AMD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None